Emergent BioSolutions (EBS) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.44 --0%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
CRVL, DD, ARDS, More
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
CRVL, DD, ARDS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $101.5 million versus the consensus estimate of $111.2 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SOPHiA GENETICS SA (SOPH) Misses Q3 EPS by 6c; Offers Guidance
- Archer Daniels Midland (ADM) Tops Q3 EPS by 20c; raises guidance
- Pfizer (PFE) Tops Q3 EPS by 14c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
